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LIGHT MEDIATED DRUG DELIVERY USING PHOTOCAGED MOLECULES AND
PHOTOSWITCHABLE PEPTIDES
Deboleena Mitra
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2014.
Advisor: Matthew C.T. Hartman, Associate Professor, Department of Chemistry
There are many different types of cancer and various methods have been developed to treat them.
Some of the methods of treatment are not highly specific and often patients suffer from various
side effects. To make the treatment more specific the method of targeted therapy has evolved. One
of the methods of targeted therapy that is highly selective as well as specific is the light mediated
treatment of cancer. Photodynamic therapy and photochemical internalization fall under this
category. Photodynamic therapy utilizes photosensitizers which operate only in the presence of
light to form cytotoxic singlet oxygen. Light of a particular wavelength activates the
photosensitizers and initiates the formation of singlet oxygen which eventually leads to cell death.
However, this approach also has some drawbacks. There are problems associated with the light to
drug administration time due to the slow uptake of the photosensitizers and the amount of
molecular oxygen in the cancer cells is in low concentration for the generation of singlet oxygen.

The method of light mediated targeted therapy that we have developed uses photocaged molecules
and photoswitchable peptides that is devoid of the above drawbacks and is highly specific.
In photocaging, a biologically active molecule is made inactive by the attachment of a
photocleavable blocking group. On exposure to UV radiation the photocleavable entity is removed
and the biologically active molecule is released. Using this concept we have designed a prodrug
that consists of a cell impermeable hydrophilic molecule attached to a photocaged doxorubicin.
The hydrophilic moiety makes the entire prodrug cell impermeable in the dark. Upon irradiation
with UV light the photosensitive group is removed and cytotoxic doxorubicin is released at the
tumor site. This concept has been further modified by attaching receptor binding molecules to the
photocaged entity to increase its specificity. Folic acid has been attached to the photocaged
doxorubicin that would interact with the folate receptors which are overexpressed in cancer cells.
These targeting groups enable cancer cell selective drug delivery with light.
A photoswitchable peptide has been used which, in the dark state is randomly coiled and cell
impermeable but upon illumination becomes helical and cell permeable and can be used to deliver
drugs into the cells. It has been established that the conformation of α helical peptides can be
controlled by azobenzene photoswitches. So azobenzene linker with iodoacetamide group has been
synthesized to link to the cysteine units of the synthesized peptides. It has also been established
that an arginine patch developed on the surface of an impermeable protein will make it cell
permeable as the positively charged arginines will interact with the heparin sulfate proteoglycans
of the cell membrane. Upon illumination with UV light of suitable wavelength the azobenzene
linker will change from a trans to a cis form and this will convert the randomly coiled cell
impermeable peptide into an α helical permeable form. Thus a series of peptides have been

designed with different arginine mutations which develop an arginine patch in the helical form.
The change in their secondary structure has been studied with circular dichroism. Cell studies
would be done in future with these peptides to verify their cell permeability. The method could
potentially be used to deliver drugs into cells in presence of light.

CHAPTER 1
INTRODUCTION

1

1.1

Cancer and its Treatment

Cancer is a disease of uncontrolled cell growth which eventually spreads to the different parts of
the body. It is a leading cause of death worldwide. According to the data sheet published by
International Agency for Research on Cancer 8.2 million people died of cancer in 2012 worldwide.
There are many reasons for the cause of cancer. The external causes include chemicals, radiation,
tobacco and infectious organisms while the internal causes are hormones, metabolic mutations, the
immune system and the mutations that have been inherited genetically. There are many ways to
treat cancer such as chemotherapy, radiation, surgery and targeted therapy.
1.1.1 Chemotherapy
Chemotherapy1,2,3 is the treatment of cancer with a drug or a combination of drugs to kill the
rapidly growing cells. Chemotherapy is often used in combination with radiation or surgery.
Chemotherapy used to shrink the tumor before radiation or surgery is called neo-adjuvant
chemotherapy. Adjuvant chemotherapy involves treatment to destroy cancer cells that remain after
surgery or radiation.
1.1.1.1

Side Effects of Chemotherapy

Chemotherapy destroys the healthy tissues also and that leads to the development of many side
effects in patients4,5,6. It affects the healthy cells of the mouth and intestine, bone marrow and cells
that are responsible for hair growth. Once these healthy cells get affected it leads to the emergence
of a series of side effects that include nausea, fatigue, hair loss and reduced blood cell count.
1.1.2 Targeted Therapy
To overcome the side effects of chemotherapy and make the treatment more specific the method
of targeted therapy7,8 has evolved. As the name suggests in targeted therapy the growth and spread
of cancer is stopped by using drugs that specifically bind to a target cancerous cells. In this method
2

there are many ways of delivering cytotoxic agents into cancer cells. Small molecular drugs are
used in targeted therapy which can cross the plasma membrane and are often used to target proteins
to affect their enzymatic activity or interaction with other substances. Imatinib mesylate (gleevec)
is one such example of a small molecule that is used in targeted therapy and it is believed to affect
the signaling pathways by targeting tyrosine kinase enzyme BCR-Abl that participates in signal
transduction. Monoclonal antibodies are also used as a vehicle to deliver radioactive molecules or
toxins inside the cancer cells. Tositumomab (Bexxar) is a radioactive immunotoxin currently
approved for therapy against certain types of non-Hodgkin lymphoma. Antibodies also can be
designed to interact with the cell surface receptors to have a direct therapeutic effect. For example,
Rituximab (rituxan) interacts with CD20 on the surface of mature B lymphocytes and triggers an
immune response against the cancer cells. Vaccines are another means of targeted therapy which
influence the immune system of the body to attach the cancer cells. Another method of targeted
therapy that is highly selective as well as specific is the light mediated treatment of cancer.
Photodynamic therapy and photochemical internalization fall under this category.

3

1.1.2.1 Photodynamic Therapy
In Photodynamic therapy (PDT)9 the treatment consists of two components-a photosensitizer and
a light of a particular wavelength that activates that photosensitizer10,11,12,13 . The photosensitizer
is administered to the body using intravenous injection or by topical application on the affected
region and then it gets absorbed by the cells and distributed all over the body. These
photosensitizers stay in the cancer cells much longer than in the normal healthy cells. Usually after
a time span of 24-72 hrs the normal healthy cells no longer retain the photosensitizer. After this
time frame the tumor is exposed to irradiation of a particular wavelength that is specific for the
photosensitizer. On absorption of the radiation the photosensitizer gets excited from the ground
state (singlet state) to a triplet state. When it relaxes back to the singlet state it releases energy to
the neighboring oxygen molecule. The oxygen absorbs the energy to form singlet oxygen that is
toxic to the cells and finally leads to apoptosis. The process has been shown in Figure 1.1.1. It
operates only in presence of light so it is highly selective. Photofrin is a FDA approved
photosensitizing agent that is used for the treatment of esophageal cancer and non-small cell lung
cancer.

4

Figure 1.1.1 Photodynamic Therapy

1.1.2.2 Disadvantages of Photodynamic Therapy
In photodynamic therapy the light that is used to activate the photosensitizers usually has moderate
ability to penetrate into tissues. Thus the use of PDT is usually limited to regions that are easily
penetrated by light such as the esophagus or tissues immediately below the skin. This limits the
use of the technique to certain regions of the body. It cannot be used if cancer has metastasized.
The effectiveness of this process also depends on the generation of singlet oxygen 14. The amount
of molecular oxygen available in cancer cells is usually not very high and hence the generation of
singlet oxygen is also low. This slows down the process of apoptosis. Lastly there is much disparity
in the light to drug administration time13 probably due to the slow uptake of the photosensitizers.
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1.1.2.3 Photochemical Internalization
Photochemical internalization (PCI)15,16,17 works on the same principle as photodynamic therapy
with the only difference that an additional toxin is present. Certain macromolecular toxins are
degraded in the endosomes before their release into the cells and this hinders the use of these
molecules in cancer therapy. To improve their therapeutic use they are used with photosentizers
that adhere to the endosomal membrane. Upon shining light of a particular wavelength these
photosensitizers generate singlet oxygen that rupture the endosomal membrane and the toxin is
released from the endosomes. This released toxin then causes cell death. The process has been
shown in Figure 1.1.2.

Figure 1.1.2 Photochemical Internalization

6

1.1.2.4 Disadvantages of Photochemical Internalization
One of the drawbacks of photochemical internalization is that a toxin molecule has to be
internalized via endosome first. This reduces the efficiency of this process. The low level of
molecular oxygen in cancer cells also affects the process as the generation of singlet oxygen is
dependent on the amount of molecular oxygen available. Lastly even in photochemical
internalization there is much disparity in the light to drug administration time13.
Thus to improve the light mediated targeted therapy some new drug delivery system needs to be
developed that is devoid of the drawbacks present in PDT and PCI. This system should not depend
on the availability of molecular oxygen in cancer cells and at the same time the disparity between
light to drug administration time should not exist.

7

1.2

Photocaged Drug Delivery System

1.2.1 Origin of Photocaged Molecules
In photocaging18 a biologically active molecule is made inactive by the attachment of a
photocleavable group. On exposure to UV radiation the photocleavable entity is removed and the
biologically active molecule is released as shown in Figure 1.2.1. The term “caged”19 was first
introduced by Joseph F. Hoffman in 1978 where he reported the development of “caged ATP”.
His work showed for the first time how the caged molecules could be used to have a spatiotemporal
control over biochemical experiments. The terminal phosphate group of ATP was attached to
photolabile groups such as 2-Nitrobenzyl and 1-(2-)nitrophenylethyl. The caged molecule in
absence of radiation was not hydrolyzed by an enzyme as it was not a substrate for that enzyme.
Upon irradiation at 340nm the photolabile group was removed and ATP was released. This
released ATP was a substrate for the enzyme and was quickly hydrolyzed by it. Since then this
idea of photocages has been used extensively to control the activity of many biological molecules.
It is an irreversible turning on of the activity of a molecule.

8

Figure 1.2.1 Release of Active Drug from Inactive Photocaged drug on exposure to UV
radiation

1.2.1 Types of Photocages
There are many photo-labile or photocaging groups that are available18. The most commonly used
photocage molecule is o-nitrobenzyl group. The reason behind its frequent use is the fact that it is
easily synthesized and can be easily incorporated in any molecule. Typically the compound used
is the nitroveratryl cage which has an m- and p- (-OCH3) groups in its structure (Figure1.2.2).
These electron donating groups shift the absorption maximum to a longer wavelength such as 365
nm. One nice application of this nitroveratryl group has been used by Lawrence and coworkers in
the photocaging of ecdysone20. Caged ecdysone would help to control gene expression with light.
A luciferase reporter controlled by ecdysone system was introduced in mammalian cells and the

9

expression of luciferase was studied in the presence and absence of light. Upon irradiation when
the natural ecdysone molecule was released it led to about 60% of luciferase expression.

Figure 1.2.2 Nitroveratryl group: Typically used nitroveratryl group in photocaging with (OCH3) groups at meta and para positions

The other type of photocaged molecules that are commonly used are the derivatives of coumarin
(Figure 1.2.3). Coumarin has been used to develop a caged mRNA that has been used by Roger
Tsien and Okamato to control the gene expression in zebrafish embryos21,22. Wen-Hong Li and
coworkers have developed caged coumarins that showed 200 fold more fluorescence enhancement
after being photolysed by UV23.
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Figure 1.2.3 Coumarin Derivative

The photocaging molecules provide an irreversible spatiotemporal control over some biological
systems. It would be good to have a reversible control over a biological system using light.
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1.3

Photoswitches in Drug Delivery

Photoswitches24,25 are molecules that switch reversibly between two different conformations when
exposed to light of a particular wavelength. They help to attain several cycles of active and inactive
state and it is usually seen in ring-opening /closing and isomerization reactions. This behavior of
the photoswitches is effectively used in controlling the spatiotemporal behavior of many
biomolecules. Some of the most commonly used photoswitches are azobenzenes, stilbenes and
spiropyrans26,27,28,29 .
1.3.1 Azobenzene Molecule as a Photoswitch
Azobenzene is one of the most commonly used photoswitches30,31,32,33,34,35,36 in biological studies.
It exists in two photoisomeric forms–the trans form and the cis form. The trans form of azobenzene
switches to the cis form when exposed to a radiation of 340 nm. The cis form thermally relaxes
back to the trans form or upon irradiation with light of 450 nm. This has been shown in Figure
1.3.1.

Figure 1.3.1 Azobenzene Photoswitch
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The trans form of the azobenzene is planar37 and has been found to be more stable than the bent
conformation adopted by the cis form by 10-12 kcal/mol. The trans form is also the dominant
isomer in the dark state.
The time needed for the unmodified cis azobenzene to thermally relax to the trans form is a few
days at room temperature. So if this azobenzene photoswitch is to be incorporated in any biological
system and a faster photoswitch is needed then this molecule needs to be modified. Much work
has been done to modify the azobenzene with different substituents.
The wavelength used to photoswitch the azobenzene molecule is in the UV range at 340 nm. At
this wavelength light does not have a good tissue penetration ability. To improve the tissue
penetration ability various substituents have been introduced in the azobenzene ring that would
red shift the absorption maximum of the compound. This shift towards higher wavelength would
improve the tissue penetration.
1.3.2 Modification of Wavelength of Azobenzene Photoswitch
The unmodified azobenzene photoswitch undergoes photoisomerization38,39 in the UV region. To
make it less harmful for the tissues during in vivo studies, substituents have to be incorporated in
the azobenzene rings to red shift the absorption maximum. This red shift of wavelength would also
improve the tissue penetration ability that was a drawback of the UV light used to photoswitch
unmodified azobenzene. The nature and position of the substituents40 on the benzene rings affect
the red shift. The presence of electron donating group at the para position of one phenyl ring and
the presence of electron accepting group at the para position of the other phenyl ring red shifts the
absorption maximum of the azobenzene ring to a great extent. The excited state for the
13

photoisomerization is charged and hence more dipolar than the ground state. When electron
donating and electron accepting groups are present in these molecules at para positions it helps in
the charge distribution of the excited state by resonance and this reduces the activation energy
barrier. So a higher wavelength of radiation is required to switch the molecule from trans isomeric
form to the cis isomeric form. An example of such azobenzene derivative is shown in Figure 1.3.2
where there is an electron donating –OCH3 group at the para position of one ring and an electron
accepting –NO2 group in the other ring.

Figure 1.3.2 4/-Methoxy-4-nitro-azobenzene

1.3.3 Modification of Azobenzene Relaxation Rate
The relaxation rates from the cis to the trans form of azobenzene molecule is of prime importance
as that would decide the type of study these azobenzene photoswitches would help to monitor. If
a fast biochemical reaction needs to be monitored that involves a pulsed conformational change
then a short lived cis isomer with a fast relaxation time is desired. Kamei and group have
developed the azobenzene photoswitch 4-(dimethylamino)-4/amidoazobenzene that has a
relaxation time of around 0.1 ms. They have introduced this photoswitch into a single stranded
14

DNA. On the other hand if a reaction needs to be sustained over several hours then an azobenzene
derivative with a longer relaxation time needs to be used.
There are many factors that affect the cis to trans relaxation rate of azobenzene. Some of these
factors are the solvents41 used, pH of the solvent42 and the nature of substituents on the phenyl
rings. The thermal transition state is dipolar in nature. Polar solvents would stabilize the dipolar
transition state and reduce its activation barrier thus making the thermal transition faster. At a
lower pH the azobenzene nitrogens would be protonated thus stabilizing the transition state and
accelerating the reaction.
The nature of the substituents present in the phenyl ring also influences the transition rate. The
presence of groups that resonance stabilize the thermal transition state reduces the activation
energy barrier and increases the rate of thermal relaxation. The dipolar nature of the transition state
for the excited state is similar to that of the thermal relaxation. So substituents that red shift the
absorption maximum also accelerate the thermal relaxation. Woolley and coworkers have
introduced many substituents at the para position of azobenzene molecule and studied the shift of
their absorption maximum and change in thermal relaxation rates43. The presence of an alkyl
carbon atom at the para position makes the absorption maximum to be 342 nm with a half-life of
43 hours for thermal relaxation. The replacement of this carbon atom with an amide group red
shifts the absorption maximum to 366 nm and the half-life of thermal relaxation changes to 12
minutes. The presence of a urea substituent at the para position changes the absorption maximum
to 382 nm and the thermal relaxation becomes extremely fast with a half-life of 80 seconds. The
structures of these compounds have been shown in Figure 1.3.3.Thus by introducing different
substituents at the para position the absorption maximum and thermal relaxation of azobenzene
photoswitches can be controlled.
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Figure 1.3.3 Azobenzene Derivative with substituents: Azobenzene derivatives with carbon
substituent (A), amide substituent (B) and urea substituent (C) at para position
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1.3.4 Use of Azobenzene Photoswitches in Controlling Peptide Conformations

Various derivatives of azobenzene molecules have been used to control the conformation of
peptides44,45. Peptides form an integral part of many biological systems and having a
spatiotemporal control over its conformation would help to modulate and study many biological
processes.
Schutt and group have cyclized a heptapeptide containing the RGD sequence (Arg-Gly-Asp) with
4-aminomethylphenylazobenzouic acid (AMPB)46,47. It is known that the RGD sequence interacts
with αVβ3 integrin- a cell surface receptor which mediates the adhesion between cells and the
extracellular matrix48. The AMPB bound RGD peptides binds to the αVβ3 with higher affinity
only when the isomer is in the trans form. This was a control over the attachment of RGD sequence
with αVβ3 using AMPB.
Woolley and coworkers have also used various derivatives of azobenzene to control the secondary
structure of peptides by attaching the linker to the peptides through cysteines placed at (i, i+4), (i,
i+7) or (i, i+11) positions49,50. Molecular modelling helped them to decide which isomeric form of
the linker was a better fit at these positions. They developed the azobenzene linker 3,3/bis(sulfonato)-4,4/-bis(chloroacetamido)azobenzene (BSBCA)51. The end to end distance of the
trans form of this linker would fit well at the (i, i+11) positions of a peptide making it helical while
the length of the cis form was not compatible with this spacing. So on exposure to UV radiation
when the trans isomer photoswitched to the cis form the helicity of the peptide decreased.
Thus much work has been done by researchers to use azobenzene derivatives in controlling the
conformation of peptides.
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1.4

Cell Penetrating Peptides in Drug Delivery

Cell penetrating peptides (CPP)52,53,54,55,56,57 are emerging as an important means of delivery of
different types of cargo like ribonucleic acids, quantum dots, nano particles or insoluble dugs into
the cells. The transport of the insoluble drugs has made the CPP more important in therapeutic
studies. Tat58, penetratin59 and nona-arginine60 are examples of some cell penetrating peptides.
CPP undergo internalization by endocytosis or by interacting with the cell surface glycans. TAT
undergoes internalization by endocytosis whereas the positively charged arginine of nona-arginine
interacts with the heparin sulfate proteoglycans of the cell membrane and enters the cell.
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CHAPTER 2
PHOTOCAGED PERMEABILITYA NEW STRATEGY FOR DRUG RELEASE

This Chapter was published under the same title in Chem. Commun., 2012, 48, 4755-4757
Authors:
M. Michael Dcona, Deboleena Mitra, Rachel W. Goehe, David A. Gewirtz, Deborah A. Lebman
and Matthew C. T. Hartman*
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2.1 Introduction
Oﬀ-target toxicity plagues conventional cancer chemotherapy. One strategy to enhance selectivity of anticancer drugs involves un-masking the cytotoxicity of a molecule in the vicinity of the tumor61. This type
of activation can be mediated by enzymes61,62, changes in pH63, or exogenous factors such as
temperature64 or light65,66,67. Light is an ideal external stimulus since it provides a broad range of
adjustable parameters68 that can be optimized for biological compliance. Several approaches that
use light for biomolecular activation have been reported69,70,71,72,73. One established method to enable
selectivity of drug action using light is photodynamic therapy (PDT). In PDT,74,9 light activation of a
photosensitizer generates cytotoxic singlet oxygen killing only illuminated cells. PDT is currently
used in several types of malignancies including skin, lung, esophageal, bladder, head and neck, and
prostate cancer. A related strategy, photochemical internalization,75,15 also uses photosensitizers. In
this case, the photosensitizers are used to release macromolecular cytotoxins from endosomes,
enabling their entry into the cytosol. However, these approaches suﬀer from disadvantages,76 including
unpredictable drug uptake rates, the limited diﬀusion and lifetime of 1O2, and the requirement for
moderate levels of O2 which may not always be available in the tumor environment.
In this communication, we report a new light-targeted drug delivery system, which operates
independently of the creation of 1O2. The basis of the system is the attachment of a cell
impermeable small molecule to a drug via a linker that can be removed in presence of light,
allowing cellular entry (Fig. 2.1). We call this new strategy photocaged permeability (PCP).
More speciﬁcally, we report the controlled release of the anti- cancer drug, doxorubicin (Dox)
(Fig. 2), upon illumination. To prevent entry of Dox in the dark we attached Dox to EDANS (Fig.
2), a small ﬂuorophore, chosen because it contains a sulfonic acid moiety known to hinder cellular
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entry.77 To connect Dox to EDANS we utilized a light-cleavable nitroveratryl (1) linker.78 The
nitroveratryl moiety has been used previously as a photocaging group for a wide variety of
biomolecules.

Figure 2.1. 1 Photocaged Permeability Strategy for Drug Delivery

Figure 2.1. 2 a). The anticancer drug doxorubicin. b). Cell-impermeable EDANS
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2.2. Materials and Methods:
2.2.1: Synthesis of Dox-EDANS Drug Conjugate:
The synthesis (Scheme 1) began with commercially available nitroveratryl carboxylic acid (1).
The N-hydroxy succinimide ester was prepared followed by coupling with propargylamine to give
amide (1). This compound was converted to the p-nitrophenyl carbonate which was then treated
with doxorubicin to generate photocaged doxorubicin carbamate (3). EDANS was coupled with
azido benzoic acid (5) and was ﬁnally attached to the photocage using click chemistry to generate
the ﬁnal Dox-EDANS conjugate (6).
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Scheme 2. 1: Synthesis of photocaged-cell impermeable drug conjugate. Reagents and conditions:
(a) NHS, EDC-HCl; (b) propargylamine, Et3N;
(c) bis p-nitrophenylcarbonate, Et3N; (d) doxorubicin-HCl, Et3N; (e) NHS, EDC-HCl; (f)
EDANS, EtN(iPr)2; (g) CuSO4·5H2O, sodium ascorbate, tris-(benzyltriazolylmethyl)amine,
DMSO : water (1 : 1).
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2.2.2 Cell Studies:
The Esophageal cancer cell line (JH-EsoAd1) was cultured at 37oC and in a humidified atmosphere
of 5% CO2 in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). For 96 well
plate experiments, the JH-EsoAd1 cells were seeded at 4450 cells/well in 100uL of media in 96
well plates; experiments were carried out one day after seeding. MTT assays were analyzed using
a Bio-Tex µQuant plate reader at 562 nm. FACS was performed BD FACS Aria II using BD FACS
Diva software at the VCU Flow Cytometry Core Facility. A minimum of 20,000 cells within the
gated region were analyzed. Confocal microscopy images were acquired at room temperature with
a Leica confocal laser scanning microscope.
2.2.2.1 Illumination Time-Dependent Toxicity:
JH-EsoAd1 cells were treated with media alone, media supplemented with EDANS (20 µM), or
media supplemented with Dox-EDANS (20 µM) in a 96 well clear-bottom, opaque plate. Cells
were exposed to light (9 mW/cm2) for various times (0-40 min) regulated by an aluminum foil
mask. During the experiment the plate was kept in ice to reduce the heating by the UV lamp. After
the lamp was turned off, the plate
was covered with foil and placed at room temperature for an additional 80 min. The media was
removed, and the cells were thoroughly washed with PBS (3x, 200µL); then 200 µL of fresh media
was added to each well. The plates were incubated for 72 hours at 37oC, following which the media
was removed and 100 µL of MTT (2mg/ml) in phosphate buffered saline (PBS) was added to each
well. After 3 hours, the MTT solution was removed and replaced with 100 µL of DMSO. The
absorbance at 562 nm was analyzed via a plate reader.
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2.2.2.2: Concentration Dependent Cell Viability Studies:
JH-EsoAd1 cells were treated with media supplemented with various concentrations of
doxorubicin (0-6.4 µM) or Dox-EDANS (6) (0-16 uM) in a 96 well clear-bottom, opaque plate.
Control wells were covered with aluminum foil while the remaining wells were exposed UV light
(9 mW/cm2) for 20 min. The plate was kept in ice during light exposure in order to minimize the
heating. After irradiation, the plate was kept at rt in the dark for another 100 minutes. The cells
were washed and treated as above (time dependent toxicity experiments) to determine viability via
the MTT assay.
2.2.2.3: Flow cytometry analysis of permeability:
JH-EsoAd1 cells were seeded at 150,000 cells/well in 1.5 mL of media in 6 well plates. The cells
were treated with media alone or media supplemented with 10 µM of EDANS-Dox (6). The plate
was placed on ice, and the light treated cells were exposed to UV light (9 mW/cm2) for 20 minutes.
Following the light exposure the plates were kept at room temperature for 100 minutes. Then, the
cells were washed with sterile PBS and trypsinized. For quantification of Dox fluorescence,
treated cells were trypsinized, harvested, and washed with PBS at approximately 1x106 cells/mL.
Pellets were fixed for 15 min at 37oC with 3% paraformaldehyde in PBS. Samples were washed
thoroughly with PBS, resuspended in PBS and analyzed by flow cytometry.
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2.2.2.4: Confocal microscopic analysis of permeability:
JH-EsoAd1 cells were seeded at 30,000 cells/well on 4 well glass chamber slides, and were treated
as above (Flow cytometry analysis). The cells were treated with media alone or media
supplemented with 10 µM of EDANS-Dox (6). The plate was placed on ice, and the light treated
cells were exposed to UV light (9 mW/cm2) for 20 minutes. Following the light exposure the
plates were kept at room temperature for 100 minutes. The cells were washed extensively with
PBS and fixed for 15 min at 37oC with 3% paraformaldehyde in PBS. Slides were rinsed, dried
and mounted under coverslips using Vectashield mounting media (Vector Laboratories, Inc.).

2.2.3: UV Lamp:
The UV lamp used in all studies consisted of a simple aquarium light fixture containing two Philips
PL-S 9w/2P BLB bulbs. The intensity of the lamp was measured in the lab of Prof. M. Bertino
(VCU) with the help of Michael Foussekis (VCU). The intensity was measured at different
distances from the lamp and was found to decrease with increasing distance from the lamp.
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Table 2.2. 1 Measurement of Intensity of UV Lamp
Distance of Photodetector

Intensity of Lamp

from UV Lamp

(mWatts/cm )

2

Exactly Below lamp

9

1 inch below lamp

6.6
3.9

3 inches below lamp
4 inches below lamp

2.8

Where diameter of the detector window was 9mm

2.3 Results
2.3.1: Effect of Light on the IC50 of Doxorubicin
The dox-EDANS drug conjugate that we would use to validate our hypothesis has doxorubicin in
it. It was important to see if the presence of the UV light affects the IC50 of doxorubicin itself in
Jh-EsoAd1 cells. The conclusion of this assay would help us compare the cytotoxicity induced in
JhesoAd1 cells by the Dox-EDANS drug conjugate under dark and light conditions with that
induced by doxorubicin itself under such conditions. In order to determine the effect of light on
cytotoxicity of doxorubicin, we treated the Jh-EsoAd1 cells with (0.025uM, .05 µM, 0.1 µM, 0.25
µM, 0.4 µM, 0.8 µM, 1.6 µM, 3.2 µM and 6.4 µM) of doxorubicin in the presence and absence of
UV lamp. The fraction of surviving cells was evaluated using the absorbance of the formazan
product of MTT reduction. The IC50 plot of the JH-EsoAd1 cells with doxorubicin in light and
dark conditions is shown in Figure 2.3.1. The cytotoxicity in the presence of UV light as shown
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by the red curve is similar to that under dark conditions as shown by the blue curve respectively
in the Figure 2.3.1. Therefore, doxorubicin is cytotoxic to the cells to the same extent under
illumination or in darkness. The value of IC50 remains 1.0 ±0.4 µM under both conditions.
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Figure 2.3.1 IC50 of Doxorubicin in Jh-EaoAd1 Cells: IC50 of Doxorubicin in Jh-EsoAd1 cells
in the presence of UV light (Red Curve) and in Dark (Blue Curve) conditions.

28

2.3.2: Effect of EDANS in Jh-EsoAd1 Cells under Light and Dark Conditions:

Since our conjugate also contain EDANS, we needed to show that it did not contribute to the
cytotoxicity in the presence of light. The cells were treated with 20µM of EDANS and the assay
was completed following the protocol mentioned in section 2.2.2.1. The effect of EDANS on the
Jh-EsoAd1 cells over this time period has been shown in Figure 2.3.2 which is an average of three
individual experiments. EDANS does not affect the cells prior to 20 minutes in the light and then
the cell viability decreases thereafter. Under the dark conditions EDANS is not cytotoxic to the
cells over the entire time period.
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Figure 2.3.2 Effect of EDANS in Jh-EsoAd1 Cells: Effect of EDANS on treatment with JhEsoAd1 cells in the presence of UV light (blue curve) and in dark (red curve).
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2.3.3: Light Dependent Cytotoxicity of Dox-EDANS on Jh-EsoAd1 Cells

We proceeded to investigate the extent to which the release of Dox with light would lead to enhanced
cellular toxicity. Indeed, increased illumination lead to decreased survival as measured by an
MTT assay as shown in Figure 2.3.5. The cells with the Dox-EDANS drug were exposed to UV light for
1min, 5 mins, 10 mins, 20 mins and 40 mins respectively. As the illumination time increased the cellular
toxicity increased and the cellular viability almost reduced to 20 at the 40th minute as shown in the curve with
solid diamonds in the figure 2.3.3. Whereas the Dox-EDANS conjugate is almost non toxic to the cells under
the dark conditions as evident from the dotted curve with open squares in the same figure. This effect was not
seen with doxorubicin and EDANS and clearly the cellular cytotoxicity is arising from the light controlled
release of doxorubicin from the Dox-EDANS drug conjugate.
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Figure 2.3.3 Light-dependent cytotoxicity of EDANS-Dox: Cells were treated with
10 mM of Dox-EDANS with (solid diamonds) or without (open squares) light for the
speciﬁed times.
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2.3.3 Concentration Dependent Cytotoxicity Study of Dox-EDANS on Jh-ESoAd1 Cells

The Jh-EsoAd1 cells were treated with Dox-EDANS drug at concentrations of 0.02 µM to 16 µM
under illumination and dark conditions. The cells were exposed to UV light for 20 minutes and
then kept incubated with the drug as mentioned in the section 2.2.2.2 (Concentration dependent
Cell Viability Studies). From Figure 2.3.4 it is clearly evident that cytotoxicity is induced in the
presence of the UV light (black diamonds) whereas in the dark (open squares) cell viability is
almost intact. The IC50 has been found to be 1.6 ± 1.0 µM

33

Figure 2.3.4 Concentration-dependent IC50 of EDANS-Dox: Cells were treated with EDANSDox at various concentrations in the dark (open squares) or with UV light for 20 min (black
diamonds).
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2.3.4 FACS and Confocal Studies to Study Cell Permeability of Dox-EDANS Drug

We then investigated whether the attachment of EDANS to Dox via the veratryl linker would enable
drug delivery. JH-EsoAd1 cells were incubated with Dox-EDANS or untreated with the drug in the
dark or with illumination. Cell permeability was measured with ﬂow cytometry; upon illumination a
signiﬁcant enhancement of cellular Dox ﬂuorescence was observed (Figures: 2.3.5; 2.3.6 and 2.3.7).
From Figure 2.3.5 it is clearly evident that the cells without the drug under light (red curve) or dark
(blue) conditions do not show enhanced fluorescence. In the presence of the drug under light (green
curve) the fluorescence intensity is enhanced compared to the dark condition (orange curve). A
Representative dot plot of the relative fluorescence intensity of EDANS-DOX in Light or Dark has
been shown in Figure 2.3.6 where the gate shown in the left panel (A) was used to derive the %
Fluorescence data shown in the right panel (B). The Dox fluorescence quantified in the right panel
(B) clearly indicates the enhanced % Fluorescence of Dox in the presence of UV light.
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Figure 2.3.5 Flow cytometry of JH-EsoAd1 cells with and without EDANS-Dox: The ﬂow
cytometry histogram displays the relative ﬂuorescence intensity of untreated controls in the dark
(blue) or light (red) or JH-EsoAd1 cells treated with EDANS-Dox in the dark (orange) or light
(green).
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Figure 2.3.6 Relative fluorescence intensity of EDANS-DOX in Light or Dark: Flow
cytometry analysis of EDANS-Dox with JH-EsoAd1 cells were performed in the dark and upon
illumination (9.0 mW/cm2) for 20 min. Left Panel (A): Representative dot plot of the relative
fluorescence intensity of EDANS-DOX in Light or Dark. The gate shown was used to derive the
% Fluorescence data shown in the right panel. Right Panel (B): Quantification of DOX
fluorescence for the indicated treatment conditions. Data are representative of two independent
experiments, N=9.
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This enhancement of fluorescence was mirrored in confocal studies with the same cell line (Figure
2.3.11); only light-treated cells show signiﬁcant Dox ﬂuorescence in the nucleus, where it is known
to accumulate.

Figure 2.3.7 Confocal images of JHEsoAd1 cells with and without EDANS-Dox: These are
representative confocal images of JHEsoAd1 cells treated with EDANS-Dox in the dark or light.
The red channel shows Dox ﬂuorescence, the gray channel is a DIC image, and the overlay
represents the cellular localization of Dox ﬂuorescence. Data are representative of two independent
experiments of N=9.
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2.4: Discussion
We have developed a new and eﬃcient strategy for drug release based on photocaged permeability
(PCP). In this first report, we have focused on applying PCP to the light-stimulated delivery of
Dox into esophageal adenocarcinoma cells.
From the FACS studies (Figures 2.3.5, 2.3.6,) it is clearly evident that the Dox-EDANS conjugate
does not enter the cells in dark. In the presence of light the nitroveratryl group is removed and the
doxorubicin is released and is cell permeable. Doxorubicin upon entering the cells interacts with
the DNA in the nucleus. The localization of doxorubicin in the nucleus in the presence of light is
evident from Figure 2.3.7.
In principle, the PCP approach could be applied to any small, cell permeable molecule that has a
free amine, hydroxyl, or carboxylic acid group for attachment of the veratryl-EDANS molecule.
Further experiments will focus on use of other light-scissile linkers that can operate at longer
wavelengths that are able to penetrate farther into tissues, as well as the use of other molecules that
block permeability.
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CHAPTER 3

PHOTOCAGED PERMEABILITY (PCP)
IN RECEPTOR MEDIATED DRUG DELIVERY
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3.1: Introduction:
Targeted therapies are being used to treat different types of diseases in order to prevent various
side effects that are part of the conventional treatments. The photocaged permeability (PCP)
concept that has been introduced in chapter 2 is specific in terms of its light controlled drug release.
To make this method dually specific we have tried to modify the conjugates such that a receptor
binding molecule is attached to the photocaged entity. The receptor binding molecule would be
specific for a particular receptor and once the drug conjugate gets internalized then upon shining
light the photocaged molecule will be removed releasing the cytotoxic doxorubicin leading to
death.
Targeted therapy is being widely used in cancer treatment where the overexpressed receptors on
cancer cells are being used for drug delivery. Folate receptor79,80,81,82,83 is one of the receptors that
are overexpressed in cancer cells. Much work has been done to develop folate-drug conjugates
that are taken up by cancer cells through the folate receptors 84. Radioactive imaging agents have
also been internalized using the folate receptors 85. The drug conjugate that we have developed has
the photocaged molecule attached to folic acid (Dox-Folate conjugate) as shown in Figure 3.1.1.
The folic acid of the drug conjugate would interact with the folate receptor and be internalized via
endocytosis. The drug is not released until the drug conjugate is exposed to light.
Beyond folic acid, this strategy would open the doors to the use of photocaged technologies
with other cell targeting molecules such as DUPA (2-[3-(1, 3-dicarboxy propyl)-ureido]) that binds
to PSMA (prostate specific membrane antigen)86 which is overexpressed in prostate cancer cells.
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Figure 3.1.1 Structure of the Photocaged Doxorubicin-Folate (Dox-Folate) Conjugate
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3.2 Materials and Methods
3.2.1 Dox-Folate Drug Conjugate
The Dox-Folate conjugate shown in Figure 3.1.1 has been used for the study.

3.2.2 Solubility and Concentration of the Doxorubicin-Folic Acid Drug Conjugate

The Dox-Folate conjugate was initially dissolved in DMSO and it was precipitating. To overcome
this problem 4 µL of 1 (N) acetic acid was added to a 20 µL solution of the drug conjugate in
DMSO. This changed the pH of the solution from 10.5 to 6.5 as indicated by the pH paper and the
precipitation of the drug conjugate stopped. So for the cell studies the drug conjugate was dissolved
in DMSO with 1(N) acetic acid.
The concentration of the doxorubicin-folic acid drug conjugate was measured on nano drop using
molar extinction coefficient of 11500 for doxorubicin in DMSO at 480nm.

3.2.2 Cell Studies
The initial experiments were done with FRα-null (R2) and FRα-(RT16) Chinese hamster cells
(CHO)87,88,89 which were obtained from Prof. Larry H. Matherly, Department of Pharmacology,
School of Medicine, Wayne State University. The R2 cells were cultured in α-minimal essential
medium (MEM) supplemented with 10% fetal bovine serum (USA Origin, heat inactivated),
glutamine and penicillin-streptomycin solution. The RT16 cells were cultured in α-MEM medium
supplemented with 10% fetal bovine serum (USA Origin, heat inactivated), glutamine, penicillinstreptomycin solution and G418 (1.5 mg/mL). For the cytotoxic assays the R2 cells were cultured
in RPMI 1640 with 10% dialyzed fetal bovine serum (USA Origin, heat inactivated), glutamine
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and penicillin-streptomycin solution for 2 passages before the cytotoxic experiments. Similarly the
RT16 cells were cultured in folate-free RPMI media supplemented with 10% dialyzed fetal bovine
serum, glutamine, penicillin –streptomycin solution and G418 (1.5 mg/mL) for two passages prior
to the cytotoxic experiments. The other cell line used for the experiments were KB-3-1 cells
obtained from Prof. Jamal Zweit, Department of Radiology, Virginia Commonwealth University.
These cells were cultured in Dulbecco’s minimum essential medium (DMEM) supplemented with
10% fetal bovine serum and penicillin-streptomycin solution. All the cell cultures were carried out
in a humidified atmosphere of 5 % CO2.
For 96 well plate experiments, the cells were seeded at 5000 cells/well in 100uL of media in 96
well plates; experiments were carried out one day after seeding. MTT assays were analyzed using
a Bio-Tex µQuant plate reader at 562 nm. FACS was performed BD FACS Aria II using BD FACS
Diva software at the VCU Flow Cytometry Core Facility. A minimum of 20,000 cells within the
gated region were analyzed. Confocal microscopy images were acquired at room temperature with
a Leica confocal laser scanning microscope.
The UV lamp used in all studies consisted of a simple aquarium light fixture containing two Philips
PL-S 9w/2P BLB bulbs placed on top of the surface of the plate.

3.2.2.1 Concentration Time point assay:
The cells were treated with media alone in a 96 well clear-bottom, opaque plate. Cells were
exposed to light (9 mW/cm2) for various times (0-120 mins) regulated by an aluminum foil mask.
During the experiment the plate was kept in ice to reduce the heating by the UV lamp. The media
was removed, and the cells were thoroughly washed with PBS (3x); then 200 µL of fresh media
was added to each well. The plates were incubated for 72 hours at 37oC, following which the media
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was removed and 100 µL of MTT (2mg/ml) in phosphate buffered saline (PBS) was added to each
well. After 3 hours, the MTT solution was removed and replaced with 100 µL of DMSO. The
absorbance at 562 nm was analyzed via a plate reader.

3.2.2.2 Flow Cytometry analysis
The cells were seeded at 200,000 cells/well in 1.5 mL of media in 6 well plates. The cells were
treated with media alone, media with 1 µM of Dox-Folate conjugate (4), media with 1 µM of
doxorubicin, media with folic acid (20 µM) + 1 µM of drug conjugate or media with 1 µM of
doxorubicin + folic Acid (20 µM) at various time points . For the inhibitory studies in presence of
folic acid at first, the cells were pre -incubated with 20 µM of folic acid for an hour and then the
drug conjugate or doxorubicin was added to the wells and incubated for time period of 30 minutes,
3 hours and 24 hours. Then, at the end of each time point the cells were washed with sterile PBS
and trypsinized. The trypsinized cells were centrifuged and resuspended in PBS supplemented
with 10% FBS at 37oC and analyzed by flow cytometry. The fluorescence of doxorubicin was used
to monitor the cell permeability of the drug. The cells were treated with media alone or media
supplemented with 1 µM Doxorubicin-Folic acid conjugate (4). The plate was placed on ice, and
the light treated cells were exposed to UV light (9 mW/cm2) for 20 minutes. Following the light
exposure the plates were kept at room temperature for 100 minutes. Then, the cells were washed
with sterile PBS and trypsinized. The trypsinized cells were centrifuged and resuspended in PBS
supplemented with 10% FBS at 37oC and analyzed by flow cytometry.

45

3.3 Results:
The transport of folates across cell membrane takes place by different receptors. Folate receptor α
(FRα)90,91,92,80 is one such receptor that helps the transport of folates across the cell membrane by
receptor mediated endocytosis. These FRα receptors are overexpressed in cancer cells. So many
folate conjugated cytotoxins or radionuclitides have targeted these FRα93,94 receptors to destroy
the cancer cells. The drug that we have designed is a Dox-Folate conjugate which is believed to
be taken up by these FRα folate receptors. In order to test for folate-receptor dependent uptake we
needed cell lines with variable folate expression. R2 cells are CHO cells where the -folate
receptor has been knocked out whereas in the RT16 cells the folate receptors are over expressed.
3.3.1 Effect of UV light on R2 and RT16 Cells
The studies of the R2 and RT16 cells with the doxorubicin-folic acid drug conjugate would be
carried out in the presence of UV light. It is important to see if the UV light has a role in causing
cell death when these cell lines are exposed to the UV light over a certain interval of time. MTT
assays were done with both R2 and RT16 cells where the cells were treated with media and
exposed to UV light over an interval of (0-120) minutes regulated by an aluminum foil mask. The
MTT assay was completed as mentioned in section 3.2.2.2. The survival plots for R2 cells and
RT16 cells have been shown in Figures 3.3.1 and 3.3.2 respectively. From the Figure 3.3.1 it is
clear that the R2 cells have a high viability close to 80 % till 40th minute and after that there is a
decrease in cell viability. For the RT16 cells the viability is close to 90% till the 80 th minute and
then there is a drop. Both these cell lines have a 100 % viability for the first 20 minutes. Thus 20
minutes was chosen to be the time frame for the experiments to be conducted with the doxorubicinfolic acid drug conjugate in order to avoid toxicity from the light.
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Figure 3.3.1 Effect of UV Light on R2 cells: R2 cells were exposed to UV light over a time
period of (0-120) minutes.
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Figure 3.3.2 Effect of UV light on RT16 cells: RT16 cells were exposed to UV light over a time
period of (0-120) minutes.

48

3.3.2 FACS Studies
3.3.3.1 Cell Permeability Studies in R2 and RT16 cells with and without Folic Acid in the
dark

We expected that folate receptor-null R2 cells would not show any uptake as they lack the folate
receptors to promote the uptake of the drug whereas the RT16 cells will show the drug uptake due
to the presence of the folate receptors. In addition, we performed studies with and without folic
acid to confirm receptor-dependent uptake at various time points (Figure 3.3.3). These studies
were performed in the dark in order to evaluate uptake prior to doing the release studies.
The results of flow cytometry experiments for R2 cells at different time points and conditions have
been shown in Figure 3.3.3. It clearly shows that neither doxorubicin alone nor Dox-Folate drug
enters the R2 cells that lack the folate receptors. For the competition studies the cells were
preincubated with folic acid for an hour prior to the addition of the Dox-Folate drug. In this study
it was found that in presence of folic acid there seemed to be a slight increase in the uptake. The
plot of % fluorescence at 24 hr time point with doxorubicin, Dox-folate drug conjugate and Doxfolate drug conjugate with folic acid has been shown in Figure 3.3.4.
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Figure 3.3.3 Histograms of R2 cells with doxorubicin, Dox-Folate + and – Folic Acid:
Histograms of R2 cells only at t=30 mins (Panel A), with doxorubicin (1 µM) at t=30 mins, 3 hrs
and 24 hrs from top to bottom (Panel B), with Dox-Folate conjugate (1 µM) at t =30 mins, 3 hrs
and 24 hrs from top to bottom (Panel C) and with the Dox-Folate conjugate (1µM) + Folic acid
(20µM, incubated for 1 hr with cells before adding the drug) at t=30mins, 3 hrs and 24 hrs from
top to bottom (Panel D)
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Figure 3.3. 4 Percentage Fluorescence Plot of R2 Cell: Plot of percentage fluorescence of
doxorubicin, Dox-folate conjugate and Dox-folate conjugate with folic acid in R2 cells.

51

The flow cytometry experiments for RT16 cells at different time points and conditions have been
shown in Figures 3.3.5 and 3.3.6. It clearly shows that both doxorubicin and Dox-Folate conjugate
in the absence or presence of folic acid do not enter the RT16 cells even though they have
overexpressed folate receptors. In the competition studies it was found that there was an increase
in the uptake of Dox-Folate conjugate (Panel C of Figure 3.3.5) and of doxorubicin in the presence
of folic acid (Panel B of Figure 3.3.6). It was necessary to do a control study where the cells were
treated with only folic acid to see if that labels the cell. The study with just folic acid (Panel C of
Figure 3.3.6) clearly shows that it does not label the RT16 cells that had the overexpressed folate
receptors. The folic acid clearly blocks the folate receptors. The plot of % fluorescence at 24 hr
time point with doxorubicin, Dox-folate drug conjugate and Dox-folate drug conjugate with folic
acid has been shown in Figure 3.3.7.
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Figure 3.3.5 Histograms of RT16 cells with doxorubicin, Dox-Folate + and –Folic Acid:
Histograms of RT16 cells only at t=30 mins (Panel A), with doxorubicin (1 µM) at t=30 mins, 3
hrs and 24 hrs from top to bottom (Panel B), with doxorubicin-folic acid drug conjugate (1 µM) at
t =30 mins, 3 hrs and 24 hrs from top to bottom (Panel C) and with the Dox-Folate conjugate
(1µM) + Folic acid (20µM, incubated for 1 hr with cells before adding the drug) at t=30mins, 3
hrs and 24 hrs from top to bottom (Panel D)
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Figure 3.3.6 Histograms of RT16 cells doxorubicin + Folic Acid, Folic Acid: Histograms of
RT16 cells only at t=30 mins (Panel A), with doxorubicin (1 µM) + Folic acid (20µM, incubated
for 1 hr with cells before adding doxorubicin) at t=30mins, 3 hrs and 24 hrs from top to bottom
(Panel B) and with only folic acid (1µM) at t=30 mins, 3 hrs and 24 hrs from top to bottom (Panel
C).
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Figure 3.3. 7 Percentage Fluorescence Plot of RT16 Cells: Plot of percentage fluorescence of
doxorubicin, Dox-folate conjugate and Dox-folate conjugate with folic acid in RT16 cells.
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We do have an explanation as to why cell permeable doxorubicin did not accumulate in the cells.
CHO cells are known to express P-glycoprotein 1 which is known to pump out doxorubicin as
soon as it enters the cell. It is likely that the Dox-Folate drug conjugate also gets pumped out of
both cell types.
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3.3.3.2 Cell Permeability Studies in KB-3-1 cells with and without Folic Acid:

Since our ultimate goal was to measure doxorubicin toxicity, we decided to change the cell line to
KB-3-1 cells. These cells have overexpressed folate receptors and are expected to uptake the drug
conjugate in the absence of folic acid.
The fluorescence of doxorubicin was used to monitor the fluorescence and study the cell
permeability via flow cytometry. From Figure 3.3.8 as expected the cells show a clear time
dependent uptake of doxorubicin. The uptake of the Dox-Folate conjugate also increases with time
as evident from panel C of Figure 3.3.8. But the inhibitory study did not give a satisfactory result.
The panel D of this figure shows that even in presence of folic acid the drug conjugate is entering
the cells which might indicate some different path of entry apart from the folate receptor for the
drug. This is all the more clear from Figure 3.3.9 which clearly shows that the drug uptake in
presence of folic acid (Panel C of Figure 3.3.9) is enhanced compared to experiments where cells
are incubated alone with the Dox-Folate conjugate (Panel B of Figure 3.3.9). The plot of %
fluorescence at 24 hr time point with doxorubicin, doxorubicin folate conjugate with and without
folic acid has been shown in Figure 3.3.8.
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Figure 3.3.8 Histograms of KB-3-1 cells with doxorubicin , Dox-Folate +and – Folic Acid:
Histograms of KB-3-1 cells only at t=30 mins (Panel A), with doxorubicin (1 µM) at t=30 mins, 4
hrs and 9 hrs from top to bottom (Panel B), with doxorubicin-folic acid drug conjugate (1 µM) at
t =30 mins, 4 hrs and 9 hrs from top to bottom (Panel C) and with the Dox-Folate conjugate (1µM)
+ Folic acid (20µM, incubated for 1 hr with cells before adding the drug) at t=30mins, 4 hrs and 9
hrs from top to bottom (Panel D)
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Figure 3.3.9 Histograms of KB-3-1 cells with Dox-Folate , Dox-Folate + Folic acid: Histograms
of KB-3-1 cells only at t=30 mins (Panel A), with Dox-Folate conjugate (1 µM) at t=30 mins, 4
hrs, 9 hrs,12hrs and 24 hrs left to right (Panel B) and with the Dox-Folate conjugate (1µM) + Folic
acid (20µM, incubated for 1 hr with cells before adding the drug) at t=30mins, 4 hrs, 9 hrs, 12 hrs
and 24 hrs from left to right (Panel D)
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Figure 3.3. 10 Percentage Fluorescence Plot of KB-3-1 Cells: Plot of percentage fluorescence
plot of doxorubicin, Dox-folate conjugate and Dox-folate conjugate with folic acid in KB-3-1 cells.
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3.4: Discussion
The FACS studies with the CHO cells showed no uptake of the drug due to the pumping out of
doxorubicin by the P-gp pumps in these cells. The P-gp95,96,97, pumps expressed on these cell
membranes identify foreign substances like drugs or toxins and pump them out of the cells using
an ATP-dependent efflux pump. To avoid this issue, the cell line was changed to KB-3-1 cells. In
these cell lines the drug was taken up by the cells but the inhibitory study in the presence of folic
acid unexpectedly showed enhanced uptake of the drug. There could be various reasons for this.
We surmise that pre-incubation of the cells with folic acid have activated endocytosis, pulling
membrane bound-drug into the cells. The relatively slow uptake of the folate-dox conjugates
suggests that this activation may be operative. Alternatively, the pre-incubation with folic acid
could have increased the folate receptor concentration on the cell surface to ultimately enhance
uptake. In either case, our inability to show selective blocking of uptake with folate led us to
abandon these experiments.

3.5 Future work
Much of the work with folate inhibitors have been done with KB85b cells. So it may be fruitful to
change the cell line to KB cells for further studies with the doxorubicin-folic acid drug conjugate.
The other point that also needs to be addressed is the drug concentration used in the FACS studies.
Most of the work done with these cell lines have folate conjugates added in nM range whereas we
had used 1 µM. We used this high concentration in order to detect the penetration of the weakly
fluorescent doxorubicin. Using such a high concentration of the drug might have enhanced nonspecific binding that increased the drug uptake and obscured the folate specific update.
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CHAPTER 4
EFFECTS OF IODOACETAMIDE
AZOBENZENE ON THE SECONDARY STRUCTURE OF
PEPTIDES
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4.1 Introduction
The α-helix is an integral part of the secondary structure of proteins and it plays an important role
in its biological function. Yet peptides excised from the a-helical domains of proteins typically do
not retain their helical structure. Many studies have been done to investigate the factors that
stabilize and enhance α-helicity in peptides. The helicity could be stabilized by adding metal
chelates, by introducing helix initiator templates or by using intramolecular peptide cross linkers
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. Verdine and coworkers have developed hydrocarbon stapled peptides with improved helicity99.

A ruthenium catalyzed olefin metathesis reaction takes place between the olefin side chains of the
amino acids to form a hydrocarbon staple that improves the helicity of the peptides. Paramjit Arora
and group have developed hydrogen bond surrogate helices where the intramolecular hydrogen
bond is replaced by a C-C bond to form a better helix100.
To have a spatial and temporal control over the secondary structure of peptides photoisomerizable
linkers have been introduced to reversibly control the secondary structure of peptides. One of the
most commonly used photoswitchable linker is azobenzene. Different derivatives of azobenzene
have been used to control the secondary structure of peptides. Woolley and coworkers have used
iodoacetamide, shown in figure 4.1.1 to improve the helicity of peptides 101. They have shown that
this linker in its trans form when introduced at (i, i+7) residues of a peptide destabilizes the helicity
as its length is too long to allow the adjacent residues to adopt an α-helical form. Whereas the
length of the cis form of the linker is compatible with the (i, i+7) spacing and increases the helicity
of the peptides and thus acts as an entropic helix stabilizer 102. The peptide with the trans form of
the linker in the randomly coiled state when exposed to UV radiation changes to the more helical
cis form as shown in Figure 4.1.2. The sequences on which most people have worked to study
change in peptide helicity upon addition of linkers have been derived from the sequence
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(EAAAR)n103 .The basic sequence (EAAAR)n is already helical due to the presence of ion pair
interactions between glutamic acid (E) and arginine (R).

Therefore it is unclear how much

contribution to the helicity is made by the azobenzene and how much is due to the intrinsic helicity
of the peptide sequence itself. We reasoned that we could investigate the role of iodoacetamide
azobenzene itself in affecting the secondary structure of peptides by systematically removing such
ion pair interactions and by comparing the uncyclized to the azobenzene crosslinked peptides in
each state.
The initial sequence that we took for our study is Ac-EACARV1AACEAAARQ-NH2 where 1=
α-amino isobutyric acid. The peptide was cyclized and circular dichroism was used to measure
the change in helicity upon cyclization under dark and light conditions. We then systematically
mutated the glutamic acids to arginine, to remove the ion pairs and replace them with the somewhat
repulsive Arg-Arg pairs. A series of such peptides have been generated with different arginine
mutations and cyclized with the iodoacetamide azobenzene linker. This study would give us an
insight into the ability of the iodoacetamide linker itself to affect the secondary structure of
peptides in the absence of helix promoting factors like ion-pair interactions.
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Figure 4.1.1 4, 4/ Iodoacetamide Azobenzene
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Figure 4.1.2 Conformational Control of Peptides by Azobenzene
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4.2 Materials and Methods

4.2.1 Synthesis of Linker
The synthesis of the iodoacetamide linker was done based on the literature report43 . 4, 4/Diaminoazobenzene (225mg, 1.2 mmol) was dissolved in 20mL of anhydrous tetrahydrofuran. It
was then stirred under argon for 15 mins and was protected from light during this time. Then
triethylamine (3 equivalents, 500uL, 3.61 mmol) was added to the above solution followed by the
dropwise addition of chloroacetyl chloride (3 equivalents, 287 µL, 3.61 mmol). The reaction was
then stirred at room temperature for another 30 minutes and then vacuum filtration was done to
remove the precipitate. The tetrahydrofuran was removed by rotary evaporation. The product
obtained was dissolved in a 1:1 solution of tetrahydrofuran and dichloromethane and was extracted
with water acidified with a few drops of 1% HCl. Anhydrous MgSO4 was use to dry the filtrate
and it was then vacuum filtered. The solvents were then removed by rotary filtration to form 4, 4/Dichloroacetamide azobenzene. Then to form the iodo derivative from the chloro derivative at first
a 20 mL solution of anhydrous acetone and 15 mL of anhydrous tetrahydrofuran were combined
and degassed. 1 g (7.1 mmol) of sodium iodide was dissolved in the above degassed solvent and
added to 150mg of dichloroacetamide acetamide. This solution was protected from light and was
stirred for 12 hrs under argon. Sodium chloride was removed by filtration and the solvent were
removed by rotary evaporation. The solid obtained was redissolved in a 1:1 solution of
tetrahydrofuran and dichloromethane and vacuum filtration was used to remove excess of sodium
iodide. The filtrate was extracted with water and anhydrous MgSO4 was used to dry it. It was
vacuum filtered, the solvent was removed by rotary evaporation and a solid product of 4, 4/iodoacetamide azobenzene was obtained.
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4.2.2 Peptide Synthesis:
Standard Fmoc-based solid phase peptide synthesis was used to make the peptides on a Liberty
Automated Microwave Peptide Synthesizer (CEM). The peptides were made on a Fmoc-Rink
amide MBHA Resin (0.65 mmol/gm). The formation of the peptides were confirmed by MALDITOF and they were purified by reverse phase HPLC on a Shimadzu system with Vydac (218TP
C18 5µ) column. The mobile phases used for the purifications were 0.1% TFA in water (A) and
CH3CN (B) and they were monitored at 215nm. The elution time for these purifications were 30
minutes. The gradients used for the purification of the peptides and the mass obtained from the
MALDI-TOF have been summarized in Table 4.2.1.
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Table 4.2.1 Linear Peptides with HPLC gradient and MALDI-TOF values
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4.2.3 Peptide Cross-Linking
Peptide crosslinking with iodoacetamide azobenzene linker was performed according to a
literature report.101 The uncrosslinked peptide (1.13 mM), Tris.Cl buffer (pH=8) and
Triscarboxyethyl phosphine (1.13 mM) were combined in a volume of 355µL and stirred under
Argon for 2 hrs to reduce the cysteine residues. To this a linker solution of 0.56 µmol in 500µL of
DMSO was added and stirred in the dark for 10 min. A second aliquot of 10 mM solution of 55.8µL
the linker was added to the solution and stirred in the dark for 10 min. Then a third aliquot of 10
mM of the same volume of linker was added and stirred in dark for 10 minutes. This was s by an
exposure of the solution to light for 20 minutes. The unreacted linker was removed by acetone
precipitation. The cyclized peptides were purified using a Shimadzu system with Vydac (218TP
C18 5µ) column using mobile phases 0.1% TFA in water (a) and CH3CN (B) and were monitored
at 370 nm. The elution time for these purification was 30 minutes. MALDI-TOF was used to
confirm the formation of the cyclized peptides. The gradients used for the purification of the
cyclized peptides and the mass obtained from MALDI-TOF has been summarized in table 4.2.2.
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Table 4.2.2 Cyclized Peptides with HPLC gradient and MALDI-TOF values
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4.2.4 Circular Dichroism
Circular Dichroism was measured on an OLIS DCM 1000spectrophotometer. All measurements
were done with a quartz cuvette of 0.1cm pathlength. The samples were dissolved in 5 mM of
phosphate buffer of pH=7. The reported spectra are an average of 3 CD experiments. The response
time was 4sec. response time. The mean residue weight of the peptide and cross-linked peptides
were assumed to be the same for the respective peptides and were calculated by dividing the
molecular weights of the peptides by the number of amino acid residues in the sequence. The
peptide concentration was measured on a nanodrop ND 1000 spectrophotometer using a molar
extinction coefficient of 28,000 for the iodoacetamide azobenzene linker in the dark state.

4.2.5 Agadir Calculation
The software Agadir (http://agadir.crg.es/) was used to calculate the percentage helicities of the
uncyclized peptides. The conditions used for the calculations include a buffer concentration of
5mM, temperature of 20oC and ionic strength of 0.03.
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4.3 RESULTS
4.3.1 Design of Azobenzene Linker
The design of the azobenzene linker has been based on the work done by Andrew G. Woolley. The
trans form of the linker is more stable than the cis form in the dark. In the paper (PNAS 2000, 8,
3803) it has been shown that the iodoacetamide azobenzene linker when attached to the cysteine
residues of the peptides at (i, i+7) positions disrupts and reduces its helicity. On shining light on
the cyclized peptide in dark for 5 minutes the linker photoswitches to the cis form and in turn
increases its helicity. We incorporated the azobenzene linker at the (i, i+7) positions of the peptides
that we designed and studied the effect of the linker on its secondary structure upon
photoisomerization.

4.3.2 Design of Peptides
We designed a series of peptides with varying number of arginines and studied the effect of the
azobenzene linker on its secondary structure. The basic sequence used was AcEACARV1AACEAAARQ-NH2 (Peptide R2) where 1=α-amino isobutyric acid (AiB) described
by Woolley101. Molecular modeling had suggested that introduction of bulky amino acids at (i,
i+3) and (i, i+4) positions between the linker attachment points would destabilize the trans
conformation further. Thus the amino acids valine and AiB were introduced at the (i, i+3) and (i,
i+4) positions with the purpose of creating steric interactions between these residues and the linker
that would further destabilize the helicity of the peptides in the dark state. So upon
photoisomerization of the linker a greater change in helicity is expected. A set of peptides were
generated from this basic sequence by systematically replacing the glutamic acid with arginine to
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replace the ion pairs with Arg-Arg repulsive pairs. The second sequence was obtained by replacing
the glutamic acids in peptide R2 to generate the peptide R4 with 4 arginines as shown in the table
4.3.1. Agadir software was used to generate the next set of peptides. It’s an algorithm based
prediction which uses the helix coil transition theory. It predicts the helicity of monomeric peptides
and takes into account factors such as pH, temperature, ionic strength, short range interactions and
also terminal modifications of the peptides. The basic sequence of peptide R2 was used and
arginine mutations were done to generate peptides with 6 and 8 arginines with the least helicity
with the purpose of studying their change in helicity upon cyclization with the azobenzene linker.
This led to the sequences of peptide R6 and R8 as shown in the table 4.3.1. The peptide R2 and
R4 when extended by amino acids AAAR along the C terminus was found to have an increased
helicity. This led to the generation of peptides R3 and R5 as shown in the table below. The
sequences used for the studies have been summarized in Table 4.3.1.
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Table 4.3.1 Peptide Sequence

Peptide Sequences
Ac-EACARV1AACEAAARQ-NH2

(Pep R2)

Ac-RACARV1AACRAAARQ-NH2

(Pep R4)

Ac-RACRRV1RACRAAARQ-NH2

(Pep R6)

Ac-RACRRV1RACRARRRQ-NH2

(Pep R8)

Ac-EACARV1AACEAAARAAARQ-NH2

(Pep R3)

Ac-RACARV1AACRAAARAAARQ-NH2

(Pep R5)

Where 1= α-Aminoisobutyric acid
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4.3.3 Effect of the Photolinker on Secondary Structure of the Peptides
The secondary structure of the peptides were measured using circular dichroism. At first the
helicity of the uncylcized peptides were measured at 20oC as shown in Figure 4.3.1. Peptide R3 is
the most helical among the six peptides with 21.2 % helicity and peptide R6 has the least helicity
of 3.5 % as shown in Table: 4.3.2. The ion pair interaction between glutamic acid and arginine
and the presence of an extra turn of the helix along the C terminus is responsible for the high
helicity of peptide R3. The replacement of the ion pair interactions between glutamic acid and
arginine with the arginine-arginine repulsive pairs reduce the helicity and thus accounts for the
less helicity in peptides R4, R5, R6 and R8.
The peptides were cyclized with the iodoacetamide linker. The circular dichroism of the cyclized
peptides were measured in dark and then they were exposed to light at 370nm for 5 minutes and
then the circular dichroism were again measured. The change in secondary structure of the linear
peptides R2, R3, R4 and R5 upon cyclization has been shown in Figure 4.3.2. It is evident that
there is not much change in helicity of peptide R2 upon cyclization as denoted by A in this figure.
The helicity of R4 and R3 decreases upon cyclization as shown by B and C in this figure. On the
other hand the helicity of R5 increases on cyclization. In peptide R4 in addition to the absence of
the Glu-Arg ion-pair interaction the trans form of the linker further reduces its helicity. Whereas
in peptide R3 the only destabilizing factor for the helicity is the trans form of the linker that reduces
its helicity to 15.1 % from 21 %. In peptide R5 the repulsive interaction between the Arg-Arg
residues is probably overcome to some extend by the trans linker that increases its helicity from
8.2 % to 14.6 %.
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Figure 4.3.1 CD of Linear Peptides: CD spectrum of Linear Peptides in 5mM Phosphate Buffer
at pH=7 and 20o C.
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Table 4.3. 2 Percentage Helicity of Linear and Cyclized Peptides
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Figure 4.3.2 CD Spectrum of linear and Cyclized peptide R2 (A), R4 (B), R3 (C) and R5 (D)
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The changes in helicity of R2, R4, R3 and R5 peptides upon photoswitching of the linker from
trans to cis form has been shown in Figures 4.3.3. In each of these peptides the trans form of the
linker changes to the cis form that is compatible with the (i, i+7) spacing and produces an increase
in helicity. The greatest change in helicity is observed for peptide R5 which changes from 14.6 %
to 38 %. This is followed by peptide R2 that changes from 13.2% to 34.1 %.
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Figure 4.3.3 CD Spectra of Peptides R2 (A), R4 (B), R3 (C) and R5 (D) under light and Dark
Conditions
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4.4 DISCUSSION
The effect of cyclization of the iodoacetamide azobenzene on the secondary structure of the
peptides can be analyzed in the following categories.
4.4.1 Effect of Arg-Glu Ion-pair Interaction and Length of Peptides
In peptides R2 and R3 favorable Arg-Glu ion pair interactions exist. Upon cyclization the helicity
of R2 does not change much whereas that of peptide R3 decreases. In peptide R3 there is an extra
turn of helix along the C terminus where an additional Arg-Glu interaction exists. The azobenzene
crosslinking position is at the cysteine adjacent to this Glu, and it is possible that a steric interaction
disrupts this helix-stabilizing ion pair. The opposite result is seen in peptide R5. In this case, the
cyclization linker appears to enhance helicity. The trans form of the azobenzene is structurally
incompatible with an alpha-helical conformation, so this enhancement is challenging to explain.
We postulate that the cyclization helps to segregate the N-terminal repulsive arginines from the
rest of the peptide by orienting them in a direction away from those in the C-terminus, enabling
the C-terminal portion to adopt a more helical structure. Thus we see that the degree of secondary
structure present in any of these sequences is a very delicate balance of the existing ion-pair
interactions, the length of the helix and the photoisomerization of the linker. In some cases the ion
pair interaction overrides the cyclization while in other cases it’s the cyclization that overrides the
ion pair interaction.
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4.4.2 Dipole-Side Chain Interaction
The helicity of a peptide also depends on the interaction between the peptide dipole and the side
chain of the amino acids. It has been found that the positive side chain of arginine when present at
the N terminus interacts with the dipole and destabilizes the α-helix and if it’s along the C terminus
then it stabilizes it. In all these peptides there is an arginine at the C terminus. So the presence or
absence of arginine along N terminus makes a contribution to its stability. In peptide R2 one
arginine is at the C terminus and the other is at the center and upon cyclization not much change
in its interaction with the dipole occurs and so the secondary structure does not change much.
R4 has an arginine along the N terminus, 2 along the center and one at the C terminus. The arginine
is almost equally distributed along the length of this peptide. Similar is the situation for peptide
R5. So not much contribution to helicity is expected from this interaction. Upon cyclization
probably the change in helicity observed in R4 and R5 is governed by other factors than this dipole
–side interaction. Thus in these two peptides it’s the balance other factors like cyclization and ArgGlu interactions that finally determine the helicity. In R3 peptide the presence of two arginines
along the C terminus makes it helical. Upon cyclization the helicity of this peptide decreases
probably a change in alignment of the arginines reduces it interaction with the dipole and so a
lesser % of helicity is obtained upon cyclization.
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CHAPTER 5

PHOTOSWITCHABLE PEPTIDES -

IN TARGETED THERAPY
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5.1 Introduction
The chemotherapeutic treatment of cancer involves a variety of methods. The lack of specificity
in the methods causes many side effects to the patients. In order to reduce these side effects and
increase the specificity of the treatment the concept of targeted therapy has developed. The
molecular targets like human epidermal growth factor receptor 2 (HER-2) are identified and are
treated with monoclonal antibodies Trastuzumab (Herceptin). Small molecular drugs like
Dasatinib (Sprycel) are used which inhibit tyrosine kinase enzymes. Cancer vaccines are another
means to treat cancer where; the vaccine activates a person’s immune system to recognize and
attack the cancer cells. Another method of targeted therapy that is highly selective as well as
specific is the light mediated treatment of cancer. Photodynamic therapy and photochemical
internalization fall under this category. In photodynamic therapy74 phosensitizers trigger the
formation of singlet oxygen upon irradiation with light of a suitable wavelength. It operates only
in presence of light so it is highly selective. It has some drawbacks as the amount of molecular
oxygen in cancer cells is often not very high. In photochemical internalization a toxin is at first
internalized in cells in the endosome and this reduces the efficiency of the process. Both in
photodynamic therapy and photochemical internalization there is much disparity in the light to
drug administration time probably due to the slow uptake of the photosensitizers and formation of
singlet oxygen. The method we have developed is devoid of the problems described above. A
photoswitchable peptide is used which, in the dark state is randomly coiled and cell impermeable,
but upon illumination becomes helical and cell permeable. Then upon entering the cell the drug
attached to the peptide would be released causing cell death.
The design of the peptides has been based on the work done by Woolley and co-workers.101 They
have designed peptides and have used 4, 4/ - bis (iodoacetamide)-azobenzene to control the helicity
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of these peptides. The linker when attached to the peptides through cysteines at (i, i +7) and (i,
i+4) position in the trans form makes the peptide less helical as their end to end distance does not
match the distance between the two cysteines. Upon exposure to UV radiation at 370 nm the trans
isomer photoswitches to the cis form. In the cis form the end to end distance of the linker matches
with the spacing between the two cysteines and this makes the peptides helical. To make the
peptides more randomly coiled in the dark state they have introduced branched amino acids like α
amino isobutyric acid (AiB) and valine at (i, i+3) and (i, i+4) positions between the cysteines which
are seven amino acids apart. The linker in the trans form interacts sterically with these branched
amino acids and further destabilizes the cyclized peptide in the dark state. Thus on
photoisomerization a greater change in % helicity is observed. It has been established by Alanna
Schepartz and group that an arginine patch developed on the helical surface of an impermeable
protein makes it cell permeable.104,105 Based on these facts and the photoswitchable peptides
designed by Woolley we have designed our peptides. We want the peptide to be randomly coiled
in the dark state and change to a helical form in the presence of light. This will be possible when
it is linked by a light sensitive linker at the (i, i+4) and (i, i+7) positions as established by molecular
modeling studies51 done by Woolley and his co-workers. The linker that we will use to control the
conformation of the peptide is 4, 4/ - bis (iodoacetamide)-azobenzene. In the trans form the peptide
is randomly coiled and upon isomerization to cis form it would make the peptide helical as shown
in Figure 4.1.2.
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The initial sequence on which the work was started was Ac-2EACARV1AACEAAARQ-NH2
where 2=Amidated cysteine and 1=α-amino isobutyric acid. To develop an arginine patch in this
sequence the amino acids would be mutated to arginine. The formation of the arginine patch is
clearly evident from the helical wheels in Figure 5.1.1 where replacement of the glutamic acids at
position 2 and 12 with arginine generates an arginine patch as shown in helical wheel B.

Figure 5.1.1 Helical Wheel of peptides 8.1 and 8.2: Helical Wheel of peptides Ac2EACARV1AACEAAARQ-NH2 (A) and Ac-2RACARV1AACRAAARQ-NH2 (B).
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The amidated cysteine denoted as 2 in the peptide sequences would serve as an attachment point
for the drug through a Cathepsin B cleavable linker. In the trans form of the linker the peptide with
the drug would be cell impermeable. Upon illumination at 370 nm the linker would change to the
cis form making the peptide helical with the arginines aligned together to form the arginine patch
that would make it cell permeable. This has been shown in Figure 5.1.2. This system could
potentially be used to deliver drugs into cells in the presence of light.

Figure 5.1. 1 Light Induced Drug Delivery
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5.2 Materials and Methods:
5.2.1 Synthesis of Linker:
The linker used is 4, 4/ - bis-iodoacetamide azobenzene and the synthesis has been done according
to the literature report. The synthesis has been reported in details in the section 4.2.1.

5.2.2. Peptide Synthesis:
Standard Fmoc-based solid phase peptide synthesis was used to make the peptides on a Liberty
Automated Microwave Peptide Synthesizer (CEM). The peptides were made on a Fmoc-Rink
amide MBHA Resin (0.65 mmol/gm). The formation of the peptides were confirmed by MALDITOF and they were purified by reverse phase HPLC on a Shimadzu system with Vydac (218TP
C18 5µ) column. The mobile phases used for the purifications were 0.1% TFA in water (A) and
CH3CN (B) and they were monitored at 215nm. The elution time for these purifications were 30
minutes. The HPLC chromatograms of the peptides and their mass spectra have been reported in
the appendix section.
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5.2.3 Peptide Cross Linking
Peptide crosslinking with the iodoacetamide azobenzene linker has been done as mentioned in
section 4.2.3. The cyclized peptides were purified using a Shimadzu system with Vydac (218TP
C18 5µ) column using mobile phases 0.1% TFA in water (a) and CH3CN (B) and were monitored
at 370 nm. The elution time for these purification was 30 minutes. MALDI-TOF was used to
confirm the formation of the cyclized peptides. The chromatograms for the purification of the
cyclized peptides and their mass spectra have been reported in the appendix.

5.2.4 Circular Dichroism
Circular Dichroism was measured on an OLIS DSM 1000 spectrophotometer. All measurements
were done with a quartz cuvette of 0.1cm pathlength. The samples were dissolved in 5 mM of
phosphate buffer of pH=7. The reported spectra are an average of 3 CD experiments. The response
time of the instrument was 4 second. The mean residue weight of the peptide and cross-linked
peptides were assumed to be the same for the respective peptides and were calculated by dividing
the molecular weights of the peptides by the number of amino acid residues in the sequence. The
peptide concentration was measured on a nanodrop ND 1000 spectrophotometer using a molar
extinction coefficient of 28,000 for the iodoacetamide azobenzene linker in the dark state at 367
nm.
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5.2.5 Removal of Acm group of Amidated Cysteine
The amidated peptide (22mg, 3µmol) was treated with TFA containing 1 % of anisole. To this
solution Ag2SO4 (80mg, 480µmol) was added and was stirred at 4oC for 2 hours. Then the solution
was concentrated under argon. Around 5mL of cold ether was used to precipitate the peptide from
the above concentrated solution. The concentrated solution was vortexed and centrifuged. The
precipitated peptide was treated with 1 mL of dithiothreitol (0.2M in 1M acetic acid) for 3 hours
at room temperature. After 3 hrs this solution was filtered and injected on HPLC. The purified
peptide obtained from HPLC was then subjected to mass spectra analysis to confirm the removal
of the acm group. The mass spectra and HPLC traces of peptide 8.5 are there in the appendix.

5.2.6 FAM5 Labelling of Peptides
The peptides were labelled with 5(6) Carboxyfluorescein (Fam-5) [shown in Figure 5.2.1]. The
labelling of the peptide was done on the resin. on which the peptide was synthesized. Fam-5 (0.3
mmoles, 112.8 mg) was dissolved in 4 mL of N, N-dimethyl formamide (DMF). It was covered in
aluminum foil and put on a tumbler for 20 minutes that would help in the dissolution of Fam-5 in
DMF. Then this Fam-5 solution was added to a tube containing the peptide-resin (0.01 mmoles,
27 mg). To this was added a solution of N, N-dicyclohexylcarbodiimide [DCC] (0.3 mmoles, 61.9
mg) dissolved in 200 µL of DMF and hydroxybenzotriazole [HOBT] (0.3 mmoles, 40.5 mg)
dissolved in 200 µL of DMF. The tube with all these contents was covered with aluminium foil
and kept on a tumbler overnight to complete the labelling of the peptide. The formation of the
labelled peptide was confirmed with Ninhydrin test. In this test some of the beads are taken in a
small test tube and washed with DMF, MeOH and DCM thoroughly. Then they were washed 3-4
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times with ethanol. Then a few drops of Kaiser solution A [20 µL KCN (13 mg dissolved in 20
mL of water) with 980 µL of pyridine and to this was added 100 µL of Pyridine/ethanol solution
(8g of phenol in 2 mL of absolute ethanol)] and Kaiser solution B [1.0 g of Ninhydrin in 20 mL of
absolute alcohol] was added. The tube was kept in a heating block at 100o C for 2 minutes. The
color of the beads were observed. The color of the beads remain yellow indicating they were
labelled with Fam-5. If the color of the bead changed to blue then that would indicate the presence
of free amine that had reacted with Ninhydrin to form the blue compound Ruhemanns blue. The
labelling method has been summarized in Figure 5.2.2.

Figure 5.2.1 Structure of 5(6)-Carboxyfluorescein
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Figure 5.2. 2 Labelling of Peptide with 5(6)-Carboxyfluorescein (FAM5)

5.2.7 Cell Studies
The Esophageal cancer cell line (JH-EsoAd1) was cultured at 37oC and in a humidified atmosphere
of 5% CO2 in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). For 96 well
plate experiments, the JH-EsoAd1 cells were seeded at 4450 cells/well in 100uL of media in 96
well plates; experiments were carried out one day after seeding. MTT assays were analyzed using
a Bio-Tex µQuant plate reader at 562 nm. FACS was performed BD FACS Aria II using BD FACS
Diva software at the VCU Flow Cytometry Core Facility. A minimum of 20,000 cells within the
gated region were analyzed. Confocal microscopy images were acquired at room temperature with
a Leica confocal laser scanning microscope.
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5.2.7.1 Fluorescence Microscopy
The cell permeability of the cyclized labelled peptide was studied initially using fluorescence
microscopy. Fam-5 Labelled Arg-9 peptide was used as a positive control as it is known to be
highly cell permeable. Olympus inverted Fluorescence microscope was used for these
experiments.
To determine the concentration of Arg9 needed to label the cells around 30,000 cells were plated
in a 3mm sterile cell culture plate. The following day the cells were treated with Arg9Fam5 peptide
at concentrations of 0.09 µM, 0.18 µM, 0.37 µM, 0.75 µM, 1.5 µM and 3 µM. The peptide was
incubated with the cells for an hour. Then the media was removed and the cells were washed with
PBS (3x) and fresh media was added. The plates were then observed under the fluorescence
microscope. The minimum concentration of Arg9Fam5 needed to label
JH-EsoAd1 cells were seeded at 5000 cells/well and treated with media alone, Fam-5 labelled
Arg9 (Arg9Fam5) peptide and Fam-5 labeled cyclized peptides in a 96 well clear-bottom, opaque
plate under light and dark conditions. Cells were exposed to light (9 mW/cm2) for various times
(0-40 min) regulated by an aluminum foil mask. During the experiment, the plate was kept in ice
to reduce the heating by the UV lamp. After the lamp was turned off, the plate was covered with
foil and placed at room temperature for an additional 80 min. The media was removed, and the
cells were thoroughly washed with PBS (3x); then 200 µL of fresh media was added to each well.
The plates were then observed under the fluorescence microscope to check the permeability of
Arg9 and Fam-5 labeled cyclized peptide.

94

5.2.7.2: Flow Cytometry Analysis for Cell Permeability:
JH-EsoAd1 cells were seeded at 200,000 cells/well in 1.5 mL of media in 6 well plates. The cells
were treated with media alone or media supplemented with Arg9Fam5 or Fam-5 labeled cyclized
peptides. The plate was placed on ice, and the light treated cells were exposed to UV light (9
mW/cm2) for 20 minutes. Following the light exposure the plates were kept at room temperature
for 100 minutes. Then, the cells were washed with sterile PBS and trypsinized, centrifuged and
resuspended in resuspended in PBS and analyzed by flow cytometry.

5.3: Results:
5.3.1: Design of peptides:
The peptide sequence on which Woolley has studied the effect of photoswitching with
iodoacetamide linker is Pep 8 of Table 5.3.1. In this peptide the cysteines are at (i, i+7) spacing.
Based on this sequence a peptides 8.1 and 8.2 (shown in Table 5.3.1) were designed where arginine
mutations were introduced to develop peptides with an arginine patch that would eventually help
in their cell permeability. We also wanted to explore the effect of the iodoacetamide azobenzene
on the helicity of the peptide when attached at (i, i+4) positions and so Pep 8.3 was synthesized.
The peptides 8.1, 8.2 and 8.3 were cyclized and then the CD data was obtained. The problem
encountered during the purification of these cyclized peptide was their extremely low yield. The
amount of peptides obtained after the removal of Acm protecting group of amidated cysteine was
extremely low. To improve the yield of the peptides it was decided to label them with a fluorescent
tag. The fluorescent tag Fluorescein-5-isothiocyanate (FITC) was added at the N terminus to form
Pep 8.4. During the cyclization of this peptide the resulting thiourea competed with the other two
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cysteines to react with the linker and thus the expected cyclized peptide was not obtained. The
sequences were further changed to Peptides 8.5 and 8.6 where FAM-5 was used as a fluorescent
label. They were cyclized and purified and a good yield was obtained. The cell permeability of
these two peptides were studied using Jh-EsoAd1 cells.
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Table 5.3. 1 Peptide Sequences
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5.3.2 Effect of Linker on Helicity of Peptides
The secondary structure of the cyclized peptides was measured using circular dichroism in before
and after irradiating with 370 nm light for 5 min.

5.3.2.1 Change in Helicity of Peptides with Linker attached at (i, i+7) and (i, i+4) position

We were interested to see how the iodoacetamide azobenzene linker would change the helicity of
peptides when attached at a (i, i+7) and (i, i+4) positions. The CD spectrum of peptides 8.1, 8.2
and 8.3 were recorded in the dark, after irradiation with UV light for 5 minutes and 30 minutes
after removal of light. The spectrum showed that the change in % helicity of peptides 8.1 and 8.2
with cysteines at (i, i+7) positions were higher than that of pep 8.3. So it was decided to pursue
further studies with peptides attached to the linker at (i, i+7) positions. Among peptides 8.1 and
8.2 a greater change in % helicity was observed for pep 8.3. The CD spectrum of peptides 8.1and
8.2 have been shown in Figures 5.3.1 and 5.3.2. The change in helicity for both peptides have been
shown in Table 5.3.2.
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Figure 5.3.1 CD Spectrum of Pep 8.1: CD Spectrum of Ac-2EACARV1AACEAAARQ-NH2
(Pep 8.1) in phosphate buffer at pH=7
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Figure 5.3.2 CD Spectrum of Pep 8.2: CD Spectrum of Ac-2RACARV1AACRAAARQ-NH2
(Pep 8.2) in phosphate buffer at pH=7
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Table 5.3. 2 Percent Helicity of Peptides 8.1 and 8.2

5.3.2.2 CD Spectrum of Pep 8.2 at 25oC and 37oC
The permeability of the peptides would eventually be studied in cells at 37oC and hence it was
necessary to see how the helicity of the peptides change at this temperature. The CD spectrum of
peptide 8.2 was measured at 25oC (Figure 5.3.3) and 37oC (Figure 5.3.4). The measurements were
done in dark, immediately after shining light for 5 minutes and readings were taken for about an
hour since the light was removed. It was found that the helicity change was greater at 25oC than
at 37oC. The % change in helicity of pep 8.2 at 25oC and

37oC has been shown in Table 5.3.3

and 5.3.4 respectively. With the rise in temperature the kinetic energy of the molecules increase
which leads to their unfolding. As the temperature increases from 25oC to 37oC the peptide 8.2
unfolds and so the helicity also reduces. Since the helicity is low at 37oC not much change in it is
observed on exposure to UV radiation when the linker photoswitches. These studies indicate that
to attain a decent amount of change in % helicity at 37oC the peptide sequence needs to be

101

modified. The simultaneous low yield of Pep8.2 also led to change the sequence to pep 8.5 and
8.6. Further CD studies would be done with these peptides.
The CD of the Fam-5 labelled cyclized Pep 8.5 gave a percentage helicity of 250.2 in dark to
266.3% upon illumination. Literature search showed that researchers working with Fam-5 labelled
peptides took the CD of the unlabeled peptides while they used the Fam-5 labelled peptide for cell
studies. Fam5 probably might interfere with the CD measurement and hence such numbers of %
helicity were obtained.
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Figure 5.3.3 CD spectrum of Pep 8.2 at 25oC: CD spectrum of Ac-2RACARV1AACRAAARQNH2 (Pep 8.2) at 25o C in phosphate buffer at pH=7

103

Table 5.3.3 Percent Helicity of Peptide 8.2 at 25oC
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Figure 5.3.4 CD Spectrum of Pep 8.2 at 37oC: CD Spectrum of Ac-2RACARV1AACRAAARQNH2 (Pep 8.2) at 37o C in phosphate buffer at pH=7
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Table 5.3.4 Percent Helicity of Peptide 8.2 at 37oC

5.3.3 Measurement of Half Life of Cyclized pep 8.2
The Half-life of the azobenzene linker in cyclized peptide 8.2 was determined using HPLC. At
first the cyclized pep 8.2 was exposed to UV radiation at 370nm for 5 minutes. Small volumes
were removed at various times for direct analysis by HPLC. At the beginning when t=0 there were
two peaks denoting the presence of both the cis and trans form of the cyclized peptide 8.2. As time
increased from 32 mins to 96 mins one of the peaks decreased indicating that the cis isomer was
thermally relaxing back to the trans isomer. The half-life was determined to be 50.58 minutes using
the plot shown in Figure 5.3.6.
Half-life was calculated using the equation y=Ae-KT where y= quantity at time t, A= quantity at
t=0, k=decay constant.
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Figure 5.3.5 Chromatograms for Cyclized pep 8.2: Chromatograms for Cyclized pep 8.2 at
1=0mins, 2=32mins, 3= 64 mins and 4=96mins.
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Figure 5.3.6 Half-life of cyclized peptide 8.2: Plot of % Cis isomer of cyclized peptide 8.2 with
time to calculate half-life of cyclized peptide 8.2
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5.3.4: Fluorescence Microscopy to Study Peptide Permeability
5.3.4.1 Concentration Dependent Permeability Study of Arg9Fam5
A concentration based permeability study of the control peptide Arg9Fam5 in JH-EsoAd1 cells
was done using fluorescence microscopy. The plates were then observed under the fluorescence
microscope. The minimum concentration of Arg9Fam5 needed to label the Jh-EsoAd1 cells was
1.5 µM as evident from Figure 5.3.7.

Figure 5.3.7 Concentration dependent study of Arg9Fam5 with Jhe-EsoAd1 cells
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5.3.4.2: Permeability Study of Fam-5 labeled Peptides
A permeability study of the Fam-5 labeled Pep 8.5, Pep 8.6, control peptide Arg9Fam5 and
negative control Fam5 was performed on JH-EsoAd1 cells. The concentration of all the peptides
used in the assay was 1.5µM. Only the cells treated with Arg9Fam5 both under light and dark
conditions were labelled as evident from Figure 5.3.8. The Fam5 labelled peptides Pep 8.5, Pep
8.6 and Fam5 itself did not label the peptides. As a concentration of 1.5µM of the labeled peptides
was used for these studies it could be possible that a little higher concentration these labeled
peptides are permeable. To validate these results flow cytometry studies were performed on JHEsoAd1 cells with the lab labeled peptides at a higher concentration.

Figure 5.3.8 Fluorescence Microscopy studies with FAM5 labelled peptides: Cell Permeability
study of Fam5 labelled Pep7, Pep8, Arg9Fam5 and Fam5 at concentration of 1.5µM
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5.3.4.3 Flow Cytometry Study of labelled Peptides
To study the permeability of the Fam5 labelled peptides JH-EsoAd1 cells were plated at 150000
cells/well in 6 well cell culture plates. The Cells were treated with only media, media supplemented
with Arg9Fam5 (1.5 µM), Pep 8.6 (Fam5-RACARV1AACRAAARQ-NH2, 40uM and 76 uM)
under dark and light conditions. For the experiments with light the cells were exposed to UV light
for 20 minutes and then were kept in dark for 100 minutes. The media was removed, cells were
washed with PBS (3x), trypsinized and then suspended in PBS for flow cytometry.
The cells were labelled extensively with ARg9Fam5 at 1.5 uM of the peptide used. On the other
hand a large amount of Pep 8.6 was used for the studies to get a sufficient amount of labelling.
From Figure 5.3.9 it is evident that there is not much difference under light and dark conditions
for Pep 8.6. As per our hypothesis it was expected that the Pep 8.6 under dark condition would not
label the cells whereas upon illumination as the linker would change to the cis form the peptide
would become helical and cell permeable. But the results obtained were contrary to our
hypothesis—the peptide was not cell permeable under either conditions.
The reason that not much difference in the light and dark condition is observed is probably because
of the peptide’s poor % change in helicity at 37 degrees.
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Figure 5.3. 9 Histogram of JH-EsoAd1 cells with FAM5-Pep8 and FAM5Arg9: Histograms
of JH-EsoAd1 cells only and with Arg9Fam5 at 1.5 µM from top to bottom of Panel A, with Pep8
(40µM) under Dark (top) and Light (bottom) of Panel B, with Pep8 (76µM) under Dark (top) and
light (bottom) of Panel C
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5.3.5 CD Studies of Peptides developed from Computational Studies
5.3.5.1 Computational Studies to Generate Peptide Sequences
Computational studies were done in collaboration with Prof. Glenn Kellogg’s lab to develop a
series of peptides that would show some change in helicity when cyclized with meta-dibromo
xylene linker. They built peptide sequences within SYBYL-X in α-helical conformation using
charged termini and using the sequence of peptide 5 as the basic sequence as shown in Table 5.3.5.
The other sequences were obtained by replacing alanine with AiB (α-amino isobutyric acid)106 as
AiB is a helix promoter. A total combination of 91 sequences were obtained using all possible
combinations by incorporating a maximum of four AiB amino acids. They were then subjected to
minimization studies under TRIPOS force field. 10 sequences were selected out of this pool to do
molecular dynamics simulation studies to predict their secondary structure. Finally a total of four
peptides were selected for CD studies from this set of 10 peptides as shown in Table 5.3.5.

Table 5.3. 5 Peptide Sequences from Computational Studies
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5.3.5.2 CD Studies of Peptides with AiB Mutations
The CD spectrum of the linear peptides obtained from computational studies clearly showed that
these peptides had a very low helicity. This has been shown in Figure 5.3.10. The percentage
helicity of the peptides were very low as shown in Table 5.3.6.
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Figure 5.3. 10 CD of Peptides 5.5.1, 5.2 and 5.3: CD Spectrum of Peptides 5, 5.1, 5.2 and 5.3 in
phosphate buffer at 20oC in phosphate buffer.
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Table 5.3. 6 Percentage Helicity of Peptides 5, 5.1, 5.2 and 5.3
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5.4 Discussion
The cell permeability studies clearly indicated that cyclized peptides were not cell permeable both
under dark and light conditions. The CD studies clearly showed that peptides had low helicity at
37oC. There are certain factors that needs to be modified in order to improve the helicity of the
peptides. The peptide lengths and nature of amino acids in the sequences can be modified. It is
also possible that the peptides had less amount of arginines in it. So if the sequence of peptide 8.5
which is Fam5-EACARV1AACEAAARQ-NH2 can be modified by introducing more arginines at
different positions and tested for cell permeability then some promising result might be obtained.
A series of such peptides have been developed as shown in chapter 4 and they need to be tested
for cell studies. Simultaneously computational studies with the basic peptide 5 with different AiB
substitutions generated a total of 4 peptides and the CD studies also showed that these peptides
had very less helicity. Computational studies with peptide 8 where the N terminus would have an
acetyl and the C terminus would have an amide and with arginines at different positions might
generate a series of peptides. The CD study with this set of peptides might give some new results.

5.5 Future Work
The basic peptide 8.5 would be mutated with arginines at various positions and labelled with Fam5
and used for cell studies on Jh-EsoAd1 cells both under light and dark conditions. At the same
time computational studies would also help to decide on the sequences of peptides to be used.
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5.6 Summary
In the first part of this thesis we have discussed the development of a new strategy called
photocaged permeability (PCP). Using this strategy we have shown the light controlled release of
doxorubicin in the esophageal adenocarcinoma cell lines. The concept of photocaged permeability
has been further developed to introduce dual specificity in the drug delivery systems. The doxphotocage would be attached to a molecule that is specific for a receptor overexpressed on the cell
surface. Thus attachment to a specific receptor and the release of doxorubicin from the internalized
drug upon exposure to radiation would make the process dually specific. Folic acid has been
attached to the photocaged doxorubicin to specifically target the overexpressed folate receptors on
the cancer cells. The photocaged doxorubicin would be further attached to different chemical
substances that are specific for other receptors overexpressed in cancer cells.
In later part of the thesis we talk about a series of designed peptides whose conformation was
controlled by the photoswitch iodoacetamide azobenzene. The secondary structure of these
peptides changed upon cyclization but did not show much cell permeability. So a new series of
peptides with different number of arginine substitutions have been developed and they would be
tested for cell permeability. Computational studies would also be done to generate a series of
cyclized peptides that might possibly show more permeability upon exposure to radiation.
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